Technical Analysis for INSY - Insys Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 0.2911 0.00% 0.00
INSY closed down 1.36 percent on Tuesday, June 18, 2019, on 2.45 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Nov 4

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical INSY trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction -1.36%
Narrow Range Bar Range Contraction -1.36%
NR7 Range Contraction -1.36%
NR7-2 Range Contraction -1.36%

Older signals for INSY ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
INSYS Therapeutics, Inc., a development stage company, develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company's cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray, a single-use product for the treatment of breakthrough cancer pain; and Dronabinol SG capsule, an ANDA approved product and Dronabinol Oral Solution, which completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting, and appetite stimulation in AIDS patients. It also develops proprietary cancer therapeutics comprising LEP-ETU, a NeoLipid liposomal, which is in Phase II clinical development stage to enhance efficacy and reduce paclitaxel-related side effects. The company was founded in 2002 and is based in Phoenix, Arizona.
Medicine Cancer Pharmaceutical Chemical Compounds Organic Compounds Oncology Pharmaceutical Products Chemotherapy Cancer Treatments Antineoplastic Drugs Euphoriants Cancer Therapeutics Vomiting Cancer Therapy Treating Cancer AIDS Paclitaxel Chemotherapy Induced Nausea
Is INSY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 11.65
52 Week Low 0.14
Average Volume 4,627,072
200-Day Moving Average 5.3281
50-Day Moving Average 2.4927
20-Day Moving Average 0.6998
10-Day Moving Average 0.5758
Average True Range 0.2986
ADX 40.35
+DI 19.691
-DI 32.7274
Chandelier Exit (Long, 3 ATRs ) 1.0042
Chandelier Exit (Short, 3 ATRs ) 1.0358
Upper Bollinger Band 1.2957
Lower Bollinger Band 0.1039
Percent B (%b) 0.16
BandWidth 170.305802
MACD Line -0.5794
MACD Signal Line -0.6453
MACD Histogram 0.0659
Fundamentals Value
Market Cap 21.16 Million
Num Shares 72.7 Million
EPS -0.22
Price-to-Earnings (P/E) Ratio -1.32
Price-to-Sales 2.18
Price-to-Book 1.57
PEG Ratio -0.62
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.48
Resistance 3 (R3) 0.49 0.44 0.45
Resistance 2 (R2) 0.44 0.39 0.43 0.44
Resistance 1 (R1) 0.36 0.36 0.40 0.36 0.43
Pivot Point 0.31 0.31 0.33 0.30 0.31
Support 1 (S1) 0.24 0.26 0.27 0.23 0.15
Support 2 (S2) 0.18 0.23 0.18 0.14
Support 3 (S3) 0.11 0.18 0.13
Support 4 (S4) 0.10